Healius Limited
Healius Limited
Your view on HLS.AX
Overview
What the company does, where it operates, and who runs it.
About Healius Limited
- Industry
- Medical - Diagnostics & Research
- Sector
- Healthcare
- CEO
- Paul D. Anderson
- Headquarters
- 161 Castlereagh Street, Sydney, NSW, AU
- Industry
- Medical - Diagnostics & Research
- Sector
- Healthcare
- CEO
- Paul D. Anderson
- Headquarters
- 161 Castlereagh Street, Sydney, NSW, AU
Healius Limited is an Australian firm dedicated to delivering specialized diagnostic services to both individual consumers and healthcare practitioners. Its operations are structured into four primary segments: Pathology, Medical Imaging, Day Hospitals, and other miscellaneous services.
The company's core offerings include comprehensive diagnostic imaging, private medical laboratory analysis, and various pathology services.
Furthermore, under a diverse portfolio of brands such as Laverty Pathology, Dorevitch Pathology, QML Pathology, Western Diagnostic Pathology, Genomic Diagnostic, Vetpath Laboratory, Vetnostics, QML Vetnostics, TML Vetnostics, ASAP Laboratory, Abbott Pathology, TML Pathology, IQ, Pathology, Kossard, Gastrolab, and Agilex Biolabs, alongside Lumus Imaging and Montserrat, Healius also facilitates a wide array of specialized surgical procedures.
These encompass cataract removal, colonoscopies, gastroscopies, plastic and cosmetic operations, skin cancer excisions, IVF egg collection, and gynecological surgeries. The company boasts an extensive network across Australia, comprising 2,105 pathology facilities, 11 day hospitals, and 134 imaging centers.
Established in 1994, the entity was originally known as Primary Health Care Limited, adopting the Healius Limited name in December 2018. Its corporate headquarters are situated in Sydney, Australia.
Stock Data
Price chart, volume, and trading data.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
About this section
Valuation, profitability, liquidity and leverage ratios for Healius Limited. Starting points for Healius Limited: EPS -AUD 0.57, beta 0.28 — an Medical - Diagnostics & Research name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
About this section
Dividend history, yield and payout sustainability for Healius Limited. Healius Limited does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
About this section
Reported vs. expected earnings history for Healius Limited. Trailing twelve-month EPS for Healius Limited stands at -AUD 0.57. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Wall Street Analyst Estimates
Analysts' price targets, ratings, and revenue and EPS estimates.
Earnings per share estimates
| Per share | This quarterSep 2025 | Next quarterDec 2025 | This yearYear to Jun 2027 | Next yearYear to Jun 2028 |
|---|---|---|---|---|
| Average estimate | AUD 0.00 | −AUD 0.00 | −AUD 0.01 | −AUD 0.00 |
| Lowest estimate | AUD 0.00 | −AUD 0.00 | −AUD 0.13 | −AUD 0.01 |
| Highest estimate | AUD 0.00 | −AUD 0.00 | AUD 0.04 | AUD 0.01 |
| Number of analysts | 0 | 1 | 4 | 5 |
| A year ago | AUD 0.07 | AUD 0.011 | −AUD 0.571 | — |
| Growth vs a year ago | −100.0% | — | — | — |
1The year-ago figure includes one-time items, so growth is not shown.
Revenue estimates
| Total | This quarterSep 2025 | Next quarterDec 2025 | This yearYear to Jun 2027 | Next yearYear to Jun 2028 |
|---|---|---|---|---|
| Average estimate | AUD 670.66M | AUD 687.16M | AUD 1.40B | AUD 1.43B |
| Lowest estimate | AUD 670.66M | AUD 687.16M | AUD 1.38B | AUD 1.41B |
| Highest estimate | AUD 670.66M | AUD 687.16M | AUD 1.43B | AUD 1.46B |
| Number of analysts | 6 | 1 | 6 | 7 |
| A year ago | AUD 998.20M | AUD 864.10M | AUD 1.37B | — |
| Growth vs a year ago | −32.8% | −20.5% | +1.9% | — |
Financial Statements
Income statement, balance sheet, and cash flow statements.
About this section
Income statement, balance sheet and cash flow history for Healius Limited. Healius Limited has reported as a listed company since 1998. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
| Ticker | Type | Company | Sector | Industry | |
|---|---|---|---|---|---|
| ACL.AXAustralian Clinical Labs Limited | Healthcare | Medical - Diagnostics & Research | — | ||
| BDX.AXBCAL Diagnostics Limited | Healthcare | Medical - Diagnostics & Research | — | ||
| CTE.AXCryosite Limited | Healthcare | Medical - Diagnostics & Research | — | ||
| GSS.AXGenetic Signatures Limited | Healthcare | Medical - Diagnostics & Research | — | ||
| IDX.AXIntegral Diagnostics Limited | Healthcare | Medical - Diagnostics & Research | — | ||
| IIQ.AXINOVIQ Ltd | Healthcare | Medical - Diagnostics & Research | — | ||
| MVF.AXMonash IVF Group Limited | Healthcare | Medical - Diagnostics & Research | — | ||
| RHY.AXRhythm Biosciences Limited | Healthcare | Medical - Diagnostics & Research | — | ||
| Ticker | Type | Company | Sector | Exchange | Mkt cap |
|---|---|---|---|---|---|
| TTOOT2 Biosystems, Inc. | Healthcare | OTC | $11,218 | ||
| TWSTTwist Bioscience Corporation | Healthcare | NASDAQ | $7.7B | ||
| VCYTVeracyte, Inc. | Healthcare | NASDAQ | $2.1B | ||
| VIMGFVimian Group AB (publ) | Healthcare | OTC | $1.5B | ||
| VRCDFVerici Dx plc | Healthcare | OTC | $4.5M | ||
| WATWaters Corporation | Healthcare | NYSE | $45.8B | ||
| WGSGeneDx Holdings Corp. | Healthcare | NASDAQ | $1.6B | ||
| WUXAYWuXi AppTec Co., Ltd. | Healthcare | OTC | $45.6B | ||
| WUXIFWuXi AppTec Co., Ltd. | Healthcare | OTC | $39.8B | ||
| XGNExagen Inc. | Healthcare | NASDAQ | $99.5M | ||
| SKHHYSonic Healthcare Limited | Healthcare | OTC | $8.2B | ||
| SLDXStella Diagnostics Inc. | Healthcare | OTC | $1.4M | ||
| Ticker | Fund | Fund assets | % of the fund |
|---|---|---|---|
| VXUSVanguard Total International Stock ETF | $163.2B in assets | 0.00% | |
| VEAVanguard FTSE Developed Markets ETF | $231.6B in assets | 0.00% | |
| ISCFiShares International Small-Cap Equity Factor ETF | $717M in assets | 0.15% | |
| VSSVanguard FTSE All-World ex-US Small-Cap ETF | $11.6B in assets | 0.00% | |
| GWXState Street SPDR S&P International Small Cap ETF | $882M in assets | 0.03% | |
| FNDCSchwab Fundamental International Small Equity ETF | $3.0B in assets | 0.01% | |
| AVDSAvantis International Small Cap Equity ETF | $379M in assets | 0.01% | |
| VPLVanguard FTSE Pacific ETF | $9.0B in assets | 0.00% | |
Largest holders first, then the funds most concentrated in HLS.AX.
News
Latest headlines and market coverage.
About this section
Latest headlines and company announcements for Healius Limited. Coverage tracks Healius Limited within Medical - Diagnostics & Research (Healthcare). Press releases and market coverage, newest first.

Comments
Comments and replies from FRC members about this company.
No comments yet
Be the first to ask a question or say what you make of Healius Limited.